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Most high-grade meningiomas show a highly perturbed copy 
number profile and they are enriched for TERT promoter 
mutations [6, 7, 11, 12]. In addition, homozygous focal dele-
tions of the cyclin-dependent kinase inhibitor 2A (CDKN2A) 
gene, located at 9p21, have been observed at high frequency 
in anaplastic meningiomas [1, 3, 4, 9, 13]. An association of 
chromosome 9p21 deletion with malignant progression of 
meningiomas and poor prognosis, specifically in anaplastic 
meningiomas, has been demonstrated in 2002 by Perry et al. 
[9]. Here, we sought to determine the overall prognostic role 
of the CDKN2A/B status in a cohort of 528 meningioma 
patients with clinical follow-up data, covering all WHO 
grades and various subtypes. We thereby intended to assess 
the predictive power of the CDKN2A/B status, both indepen-
dently and in the context of WHO grading, TERT promoter 
mutation status, and DNA methylation-based classification.
Tumor tissue and clinical follow-up data from 528 
patients were obtained from the archives of multiple interna-
tional collaborating centers and collected at the Department 
of Neuropathology, University Hospital Heidelberg (Hei-
delberg, Germany). Analysis of tissue and clinical data was 
performed in accordance with local ethical regulations. The 
clinical and pathologic characteristics of the study patients 
are summarized in Supplementary Table 1, online resource. 
DNA methylation profiling and copy number analysis of 
the tumors were performed using the Infinium Methylatio-
nEPIC (850k) BeadChip (Illumina, San Diego, CA, USA) 
or Infinium HumanMethylation450 (450k) BeadChip (Illu-
mina) array as reported [2]. TERT promoter mutation status 
was assessed by Sanger sequencing or panel sequencing as 
previously described [5, 10]. Distribution of time to pro-
gression (as determined by imaging) or recurrence (TTP) 
after surgery was estimated by the Kaplan–Meier method 
and compared between groups with the log-rank test. Mul-
tivariable Cox proportional hazards regression was used to 
estimate the prognostic impact after adjusting for established 
prognostic factors. p values less than 0.05 were considered 
significant.
Among the tumors of 528 patients included in this study, 
26 (4.9%) showed a homozygous deletion of CDKN2A/B 
as determined by DNA methylation array. Seven (27%) of 
these tumors were histologically graded as WHO grade II 
and 19 (73%) as WHO grade III. Notably, all tumors were 
either classified as atypical (constituting 4% of all atypical 
meningiomas) or anaplastic meningiomas (28% of all ana-
plastic meningiomas). Besides the most common grading 
criterion, proliferative activity, a set of morphological fea-
tures also qualifies for WHO grade II or III according to the 
WHO classification, even in absence of high mitotic count. 
Interestingly, none of the WHO grade II or III meningioma 
variants diagnosed according to the proliferation-independ-
ent histological patterns, including chordoid, clear cell and 
rhabdoid meningiomas, showed a homozygous deletion of 
CDKN2A/B (Supplementary Table 1, online resource). In 
relation to the different methylation classes reported to inde-
pendently stratify for risk of recurrence among meningioma 
[12], CDKN2A/B homozygous deletion was observed only 
in the methylation classes “intermediate” (n = 6; 23%) or 
“malignant” (n = 20; 77%). None of the tumors within the 
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methylation class benign showed a homozygous deletion of 
CDKN2A/B. Of the 528 patients, 350 were female (66%) 
and the mean age at the time of surgery was 57 years (range 
6–85 years). Median follow-up after surgery was 45 months 
(range 1–291 months), during which 175 patients had a pro-
gression or recurrence. Homozygous deletion of CDKN2A/B 
was neither significantly associated with patient age or sex 
nor with the tumor location. A detailed description of clin-
ico-pathological characteristics is given in Supplementary 
Table 2, online resource.
Patients whose tumors carried CDKN2A/B homozygous 
deletions had a significantly worse outcome and more rapid 
progression from the time of surgery (p < 0.001; median TTP 
8 vs. 101 months, Supplementary fig. 1, online resource). 
Importantly, this held true even within WHO grades (WHO 
grade II/III: p = 0.004/0.003; Fig. 1a, b). A significant dif-
ference was also observed within DNA methylation-based 
subtypes (intermediate/malignant: p = 0.03/0.02, corre-
lation of these and other parameters depicted in Fig. 1c). 
CDKN2A/B status remained an independent prognostic fac-
tor in Cox regression when adjusting for WHO grade, DNA 
methylation-based classification, tumor location, age and sex 
(Supplementary Table 3, online resource).
As TERT promoter mutations are associated with early 
recurrence [8, 11], we evaluated the effects of the TERT 
status on the TTP in a subset of patients (n = 293, 16 with 
CDKN2A/B homozygously deleted tumors) with available 
sequencing data, both individually and combined with 
the CDKN2A/B status. Tumors of 6/293 patients carried a 
TERT promoter mutation, three of them showed co-occur-
rence of a homozygous deletion of CDKN2A/B (p = 0.002). 
The outcome of patients with TERT promoter-mutant 
tumors was similarly unfavorable as that of patients with 
CDKN2A/B homozygously deleted tumors (median TTP 
for TERT, CDKN2A/B homozygous deletion, and other 
(i.e. none of both alterations): 11.5, 8, and 147 months, 
respectively; TERT status illustrated in Supplementary 
Fig. 2, online resource).
Our data demonstrates an independent adverse effect 
of CDKN2A/B homozygous deletion on the time to pro-
gression of patients with meningiomas. Thus, CDKN2A/B 
status can provide a useful biomarker for the identification 
of meningioma patients with a high risk of early recur-
rence. Consistent with previous studies, homozygous 
deletion of CDKN2A/B was found mainly in meningiomas 
graded as WHO grade II or III [1, 9, 13] which under-
lines a potential role in the malignant transformation of 
meningiomas. However, further studies will be needed for 
identification of the decisive steps in meningioma pro-
gression which will additionally assist in prioritizing the 
most relevant targets for novel therapy approaches. So 
far, CDKN2A/B homozygous deletion itself may be fur-
ther clinically investigated as target for inhibitors of the 
CDK4/6 axis, e.g. ribociclib or palbociclib.
Notably, CDKN2A/B homozygous deletion allowed to 
further discriminate patients with unfavorable outcome 
within WHO grade II and III cases. This may suggest 
CDKN2A/B deletion as independent criterion for identifi-
cation of highly aggressive (i.e. WHO grade III) meningi-
omas. However, a major limitation in the value of testing for 
CDKN2A/B homozygous deletion as well as TERT promoter 
mutation, both relevant to identify high-risk cases, is the low 
frequency of cases harboring such alterations. Furthermore, 
there seem to be a very small number of cases showing con-
cordant alterations of CDKN2A/B and TERT which necessi-
tates evaluation of both markers for a reliable risk prediction.
Interestingly, CDKN2A/B homozygous deletion further 
stratified for cases with highest risk of recurrence even 
within the methylation classes intermediate and malignant 
(Supplementary Fig. 3, online resource). This indicates that 
risk prediction based on methylation classes can be further 
refined when incorporating CDKN2A/B status, which will 
typically be available concurrently with generating methyla-
tion array data. Assessment of CDKN2A/B alone, however, 
cannot achieve the same prediction accuracy as methylation, 
since cases without homozygous deletion can still fall in any 
of the epigenetic classes.
In conclusion, our study demonstrates that homozygous 
deletion of CDKN2A/B is highly prognostic in meningiomas 
and may be a useful, independent molecular biomarker for 
grading of these tumors.
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Fig. 1  Time to progression or recurrence (TTP) of the 528 patients in 
the cohort stratified for CDKN2A/B homozygous deletion vs. WHO 
grade (a, b). Forest plot of univariable (unadjusted) hazard ratios for 
TTP for CDKN2A/B homozygous deletions stratified by WHO grade, 
methylation classes, TERT promoter mutation status, sex, age and 
location (c). AgeT gives age tertiles. IA p value gives p value for test 
on interaction, i.e., different prognostic effect of CDKN2A/B homozy-
gous deletion in subgroups. MC methylation class, ben benign, int 
intermediate, mal malignant, F female, M male, TTP time to progres-
sion/recurrence
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